New hope for men with Tough-to-Treat prostate cancer

NCT ID NCT03480646

Completed Disease control Sponsor: Constellation Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study tested a new oral drug, CPI-1205, in combination with standard prostate cancer medications (enzalutamide or abiraterone/prednisone). It involved 175 men whose advanced prostate cancer had spread and was no longer responding to standard hormone therapy. The goal was to find a safe and effective dose and see if adding CPI-1205 could help control the cancer better than the standard drugs alone.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Alaska Urological Institute

Anchorage, Alaska, 99503, United States
Beverly Hills Cancer Center (BHCC)

Beverly Hills, California, 90211, United States
Carolina Urologic Research Center

Myrtle Beach, South Carolina, 29572, United States
Compass Oncology - East

Tualatin, Oregon, 97062, United States
Comprehensive Cancer Centers of Nevada

Las Vegas, Nevada, 89135, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02115, United States
Duke University Medical Center

Durham, North Carolina, 22710, United States
Eastchester Center for Cancer Care

The Bronx, New York, 10469, United States
GU Research Network

Omaha, Nebraska, 68130, United States
Gettysburg Cancer Center

Gettysburg, Pennsylvania, 17331, United States
Greenville Hospital System, Institute for Translational Oncology Research

Greenville, South Carolina, 29605, United States
H. Lee Moffitt Cancer Center & Research Institute

Tampa, Florida, 33612, United States
Henry Ford Health System

Detroit, Michigan, 48202, United States
Icahn School of Medicine at Mt. Sinai

New York, New York, 10029, United States
Indiana University- Simon Cancer Center

Indianapolis, Indiana, 46202, United States
John Hopkins Kimmel Cancer Center

Baltimore, Maryland, 21205, United States
John Wayne Cancer Inst.

Duarte, California, 91010, United States
Levine Cancer Institute

Charlotte, North Carolina, 28204, United States
Maryland Oncology Hematology

Rockville, Maryland, 20850, United States
Mount Sinai Comprehensive Cancer Center

Miami, Florida, 33140, United States
NYU Langone Medical Center Laura and Isaac Permlutter Cancer Center

New York, New York, 10016, United States
New Mexico Cancer Center

Albuquerque, New Mexico, 87106, United States
North Shore Hematology Oncology Associates

East Setauket, New York, 11733, United States
Ohio State University - James Cancer Hospital and Solove Research Institute

Columbus, Ohio, 43210, United States
Rocky Mountain Cancer Centers

Aurora, Colorado, 80045, United States
Roswell Park Comprehensive Cancer Center

Buffalo, New York, 14263, United States
Rush University Medical Center

Chicago, Illinois, 60612, United States
St. Luke's University

Bethlehem, Pennsylvania, 18015, United States
Texas Oncology - Central Austin Cancer Center

Austin, Texas, 78731, United States
Texas Oncology- Fort Worth

Fort Worth, Texas, 76104, United States
Texas Oncology- Tyler

Tyler, Texas, 75702, United States
Toledo Clinic Cancer Center

Toledo, Ohio, 43623, United States
Tulane University Health Sciences Center

New Orleans, Louisiana, 70112, United States
UCLA

Los Angeles, California, 90095, United States
University of Colorado Hospital - Anschutz Cancer Pavilion

Aurora, Colorado, 80045, United States
University of Florida

Jacksonville, Florida, 32209, United States
University of Illinois Hospital and Health Systems

Chicago, Illinois, 60612, United States
University of Maryland

Baltimore, Maryland, 21201, United States
University of North Carolina-Chapel Hill

Chapel Hill, North Carolina, 27599, United States
Virginia Oncology Associates

Hampton, Virginia, 23666, United States
Williamette Valley Cancer Institute and Research Center

Eugene, Oregon, 97401, United States

Conditions

Explore the condition pages connected to this study.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)